EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document 52021XC1129(01)

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (OJ L 396, 30.12.2006 , p. 1.)) (Text with EEA relevance) 2021/C 480/06

C/2021/8269

OJ C 480, 29.11.2021, p. 6–6 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

29.11.2021   

EN

Official Journal of the European Union

C 480/6


Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2021/C 480/06)

Decision granting an authorisation

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2021) 8269

22 November 2021

Chromium trioxide

EC No. 215-607-8, CAS No. 1333-82-0

ThyssenKrupp Electrical Steel GmbH Kurt-Schumacher-Straße 95, 45881, Gelsenkirchen, Northrhine-Westphalia, Germany

Thyssenkrupp Electrical Steel UGO S.A.S.,

Rue Roger Salengro, 62330 Isbergues, France

REACH/21/3/0

REACH/21/3/1

As surface treatment for the manufacture of grain-oriented electrical steel used in magnetic cores of high-performance transformers and related electromagnetic devices

31 December 2029

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health from the use of the substance and there are no suitable alternative substances or technologies.


(1)  OJ L 396, 30.12.2006 , p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu).


Top